Phase 2a study of first-in-class direct AMPK activator in the treatment of non-alcoholic steatohepatitis (NASH) meets primary endpoint

In the STAMP-NAFLD study of patients with NASH with or without diabetes (n=120), PXL770 was associated with a mean decrease of 18% in liver fat mass at 12 weeks in the 500mg once-daily dose group (v -0.7% with placebo; p=0.0036).

Source:

Biospace Inc.